
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Basel, Switzerland—Roche, which recently slashed its work force by 3,000, maintains that it will remain independent even after the sale of 20 percent of the company to Novartis. Franz Humer, the troubled company’s chairman, says the founding family supports Roche’s strategy.
over 25 years ago
Pharmacies: OTC Price Warsover 25 years ago
One Disease at a Timeover 25 years ago
Overview of the Industry: A World of Opportunitiesover 25 years ago
The Power Shiftover 25 years ago
Overruled: No More Dual Pricingover 25 years ago
Submergedover 25 years ago
Generic Threat





